Regulatory Story
Go to market news section View chart   Print
Proteome Sciences PLC  -  PRM   

Trading Statement

Released 07:00 22-Jan-2013

RNS Number : 0446W
Proteome Sciences PLC
22 January 2013




Proteome Sciences plc

("Proteome" or the "Company")

Trading Update

22nd January, 2013- The Directors of Proteome provide the following trading update.

Following the Company's announcement on 31 December 2012(RNS: 4741U), regarding the improved cognitive function demonstrated by Proteome's CK1D compounds, the Board has been pleased by the strong interest it has received from pharmaceutical companies.  The Board is actively pushing the CK1D programme forward with the pharmaceutical industry in order to be able to bring the compounds to clinical trials.  Discussions have commenced to out license the CK1D programme as soon as possible in 2013 and the Directors expect that the novel nature of the compounds in the tau pathway should materially increase the Company's IP asset value.  Industry benchmarks indicate that these should command considerable license fees, milestones and royalties.  Analysis of the 1,000 Alzheimer's patient sample set with King's College is on-going and further results will be announced when the data processing is completed.

The Directors are encouraged by the trading prospects for the PS Biomarker Services™ division although they are disappointed that the signing of the largest services contract negotiated by the Company to date which had been expected to close at the end of 2012 has been delayed and is now expected to be concluded in Q1 2013.  As a result of this delay there will be an adverse impact on the Company's results for the year ended 31 December 2012 although this will have a correspondingly positive effect on the Company's expectations for FY13.

Christopher Pearce, the Company's Chief Executive Officer, has confirmed his willingness to provide additional working capital should it be required, by way of a short term loan of up to £1 million. This would be repayable post receipt of the proceeds of the major contract referred to above.

One of the Board's main objectives for FY 2013 is outlicensing the Company's proprietary IP.  The single use of GSTP in blood as a test to confirm a stroke within 15 minutes and its ability to potentially increase the most effective thrombolytic treatment rt-PA more than fivefold has now extended the licensing discussions to pharma, in addition to the major diagnostics companies which have already been targeted for the Company's existing stroke panels.  This is expected to materially increase Proteome's licensing activities.

The Board expects strong revenue growth across the Company's three main divisions in 2013 and looks to the future with confidence.

- Ends -

For further information please contact:

Proteome Sciences plc

Christopher Pearce, Chief Executive Officer

Tel: +44 (0)1932 865065

Dr. Ian Pike, Chief Operating Officer

James Malthouse, Finance Director

Nominated Adviser


Stephen Keys/Camilla Hume

Tel: +44 (0)20 7397 8900

Public Relations

FTI Consulting

IKON Associates

Ben Atwell / Simon Conway / Mo Noonan

Adrian Shaw

Tel: +44 (0)20 7269 7116

Tel: +44 (0)1483 271291


Notes to Editors:

About Proteome Sciences

Proteome Sciences is a global leader in applied proteomics and peptidomics offering high sensitivity, proprietary technologies for protein and peptide biomarker discovery, validation and assay development.

Its PS Biomarker Services™ uses isobaric and isotopic Tandem Mass Tag® (TMT®) workflows developed on the latest Orbitrap Velos and TSQ Vantage mass spectrometers to deliver rapid, robust and reproducible biomarker assay development for customers in the pharmaceutical, diagnostic and biotechnology sectors. Services are provided from its ISO 9001: 2008 accredited facilities in Frankfurt, Germany. By combining Selected Reaction Monitoring (SRM) and TMT® workflows highly multiplexed assays can be developed rapidly and are suitable for screening hundreds of candidate biomarkers in larger validation studies and can be transferred for immunoassay development. The Company's own research has discovered a large number of novel protein biomarkers in key human diseases and is focused mainly in neurological/neurodegenerative conditions and in cancer. It has discovered and patented blood biomarkers, including Alzheimer's disease, stroke, brain damage and lung cancer for diagnostic and treatment applications that are available for license or are already outlicensed. Proteome Sciences, based in Cobham, UK, with facilities in London and Frankfurt, delivers outsourced proteomics services and proprietary biomarkers/biomarker assays to pharmaceutical, biotechnology and diagnostics companies.


This information is provided by RNS
The company news service from the London Stock Exchange

London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. Terms and conditions, including restrictions on use and distribution apply.


Trading Statement - RNS